Skip to content
Drug Policy Watch™
LatestTracking drug policy in all 50 states and Congress, updated every morning.See all ›
Drug Policy Watch · State Brief 2026

New Mexico

Snapshot (structured)

Adult-use cannabis
Legal, retail sales since April 1, 2022 (Cannabis Regulation Act, 2021).
Medical cannabis
Legal since 2007 (Lynn and Erin Compassionate Use Act); medical product is exempt from excise and gross receipts tax.
Home grow
Allowed, up to 6 mature and 6 immature plants per adult, capped at 12 mature plants per household.
Intoxicating hemp / hemp THC
Tightening; a September 1, 2025 NM Environment Department emergency rule bans chemically converted/synthetic cannabinoids (delta-8, delta-10, THC-O, HHC). State exposed to the federal hemp redefinition effective November 12, 2026.
Psychedelics
Medical Psilocybin Act (SB 219) signed April 2025; supervised therapeutic access only, no broad decriminalization. Program targeted to launch by December 2026.
Broad decriminalization
No. Personal possession of most controlled substances other than cannabis remains a misdemeanor or felony.
Harm reduction
Strong. Long-standing Harm Reduction Act; syringe services, naloxone (free by mail), fentanyl and xylazine test strips legal.
Governor (party)
Michelle Lujan Grisham (Democrat); term-limited, leaves office January 2027.
Legislature control
Democratic in both chambers (Senate roughly 26 D to 16 R; House roughly 44 D to 26 R).
Citizen ballot initiatives allowed
No initiative for new laws; only veto referendum on enacted statutes.
Enclosure pressure score
3/5

Cannabis

New Mexico legalized adult-use cannabis through the Cannabis Regulation Act (HB 2), signed in 2021, with retail sales beginning April 1, 2022. Medical cannabis has been legal since 2007 under the Lynn and Erin Compassionate Use Act. Adults 21 and over may possess up to 2 ounces of flower in public and grow up to 6 mature and 6 immature plants per person, capped at 12 mature plants per household.

Market structure is unusually open by national standards. There are no statewide license caps, no residency requirement, and the law explicitly authorizes vertical integration. License classes administered by the Cannabis Control Division (CCD) include Producer (cultivation), Manufacturer, Retailer, Courier, Testing Laboratory, Consumption Area, Producer Microbusiness, Integrated Cannabis Microbusiness, and Vertically Integrated Cannabis Establishment. The microbusiness and integrated microbusiness tiers (small grow plus manufacture plus retail, plant-count limited to 200 mature plants for a producer microbusiness) were designed to let small operators enter cheaply, and the state has issued large numbers of these. Multistate operators are present but the market is not MSO-dominated, in part because low barriers produced a flood of small licensees.

Taxes: a state Cannabis Excise Tax applies to adult-use sales, set at 13% as of July 2025 and scheduled to rise 1 percentage point per year to 18% by 2030, on top of state and local gross receipts tax (roughly 5% base, varies by locality). Medical sales are exempt from the excise tax and gross receipts tax.

Key 2026 actions: The 2026 regular session was a 30-day, primarily budget-focused session (January 20 to roughly February 19, 2026). Reported cannabis-related measures that session leaned toward tightening rather than expansion, including a child-safety packaging proposal (reported as HB 294, black-and-white packaging and a ban on youth-appealing designs) that did not pass. Note that the well-publicized medical-cannabis workplace protection bills HB 230 (Rep. Reena Szczepanski and Rep. Elizabeth Thomson) and SB 269 (Sen. Linda Lopez) were 2025-session bills (HB 230 passed the House March 12, 2025); their final 2025 enactment status is unconfirmed in the sources reviewed and should be verified on the live tracker.

Hemp

New Mexico has not enacted a blanket statutory ban on all intoxicating hemp, but it has moved aggressively by rule. The New Mexico Environment Department (NMED) issued an emergency amendment to its hemp regulations effective September 1, 2025 that prohibits the manufacture and sale of chemically converted or synthesized cannabinoids, expressly naming delta-8 THC, delta-10 THC, THC-O, HHC and similar compounds. Naturally occurring hemp at or below 0.3% delta-9 THC by dry weight remains within the state Hemp Manufacturing Act framework. Albuquerque separately passed a June 2025 city ordinance restricting unregulated synthetic hemp sales and imposing age-21 controls.

Federal exposure: Congress redefined hemp in Section 781 of the appropriations law signed November 12, 2025, shifting to a total-THC standard (0.3% total THC including THCA) and capping final-form hemp products at 0.4 mg total THC per container. That change takes effect November 12, 2026, after which products outside the new definition could face Controlled Substances Act enforcement. As of the most recent reporting, the 2026 Farm Bill advancing in the U.S. House left the intoxicating hemp ban untouched (House Agriculture Committee advanced it 34-17 on March 5, 2026). New Mexico's already-restrictive 2025 rule means the state is comparatively well-positioned for the federal change, but the November 12, 2026 deadline still threatens the remaining low-dose hemp THC market sold outside licensed cannabis channels. A 2026 state hemp bill, reported as HB 346 (amending hemp finished-product definitions, banning semi-synthetic and synthetic cannabinoids, and creating hemp-retailer regulation under NMED and the Environmental Improvement Board), was under consideration; its final status is unconfirmed and should be verified on the tracker.

Psychedelics

New Mexico became the third U.S. state (after Oregon and Colorado) to authorize therapeutic psilocybin when Gov. Lujan Grisham signed the Medical Psilocybin Act, Senate Bill 219, in April 2025. It is the first such program created directly by a legislature rather than by ballot initiative. The program is a tightly controlled medical-access model, not decriminalization: a patient must be professionally diagnosed with a qualifying condition (major treatment-resistant depression, PTSD, substance use disorder, end-of-life care, and other conditions the department may add), and psilocybin must be administered by a New Mexico-licensed health care provider in an approved clinical setting.

The Department of Health is writing the rules through a Medical Psilocybin Advisory Board, which held its first public meeting December 5, 2025. SB 219 set a statutory deadline of December 31, 2027, but officials announced plans to launch by the end of December 2026, roughly a year early, citing high demand. The 2026 session secured about $630,000 for an equity fund to reduce treatment-cost barriers. No broad psychedelic decriminalization is in force, and no separate 2026 decriminalization bill is confirmed in the sources reviewed.

Broader drug policy

Decriminalization: New Mexico has not decriminalized possession of controlled substances generally. Under Chapter 30, Article 31 of the statutes, possession of a Schedule I or II narcotic or PCP can be a third-degree felony (up to 3 years), other felony possession can be a fourth-degree felony (up to 18 months), and many possession offenses are misdemeanors (up to 364 days). Drug specialty (treatment) courts are available.

Harm reduction: This is a relative strength. New Mexico was an early adopter of harm reduction via its Harm Reduction Act, and the Department of Health operates statewide syringe services, naloxone distribution (available free by mail through NMHarmReduction.org), and drug-checking supplies. Fentanyl test strips were authorized through legislation (a 2022-era reform), and recent legislation (reported as HB 52, amending the Harm Reduction Act to expand drug-checking supplies such as fentanyl and xylazine test strips) further broadened access; the exact session/enactment of HB 52 is unconfirmed in the sources reviewed and should be verified. The NM Pathways program expands Medication for Opioid Use Disorder access, including in rural, frontier, and Tribal communities.

Sentencing and expungement: The Cannabis Regulation Act included automatic expungement of prior cannabis convictions now legal, though implementation has lagged; a 2023 law lets people check status and request faster processing. Broader controlled-substance sentencing reform is not confirmed for 2025-2026.

Political landscape

Governor: Michelle Lujan Grisham (Democrat), term-limited and leaving office in January 2027; the 2026 session was her last. She has been a signer of major reform, including the 2021 legalization law and the 2025 Medical Psilocybin Act, and broadly signs most cannabis and harm-reduction legislation reaching her desk.

Legislature: Democrats control both chambers. The Senate is roughly 26 Democrats to 16 Republicans; the House roughly 44 Democrats to 26 Republicans. Leadership includes House Speaker Javier Martinez (D) and Senate leadership under Senate President Pro Tempore (Sen. Mimi Stewart) and Majority Leader (Sen. Peter Wirth) per recent sessions, though specific 2026 leadership assignments should be verified; the search returned a reference to "Senate President Howie Morales (D)," but Howie Morales is the Lieutenant Governor (who presides over the Senate), so that should be treated as unconfirmed.

Reform champions: Rep. Reena Szczepanski (D, House Majority Floor Leader) and Rep. Elizabeth Thomson (D) pushed medical-cannabis workplace protections (HB 230); Sen. Linda Lopez (D) carried the Senate companion (SB 269). Sponsors of the Medical Psilocybin Act (SB 219) are unconfirmed in the sources reviewed and should be verified before naming. Named opponents are not clearly identified in the sources reviewed; opposition to the 2026 packaging restrictions came partly from cannabis industry voices arguing child-safety is "not black and white," but no individual legislator-opponent is confirmed.

Ballot initiatives

New Mexico does not allow citizen-initiated ballot measures to create new statutes or constitutional amendments. The only citizen tool is the veto referendum, which lets voters repeal an already-enacted statute (signature thresholds of about 10% of registered voters to refer, 25% to suspend the law pending the vote, and not usable on emergency legislation). Constitutional amendments must be referred by the legislature. Consequently, all New Mexico cannabis, hemp, and psychedelic policy comes through the legislature, not the ballot box, and there are no pending citizen drug-policy ballot measures.

Equity and expungement

Social equity: The Cannabis Regulation Act and CCD created a social-equity framework, including discounted microbusiness and integrated-microbusiness licenses intended to lower the cost of entry for small and disadvantaged operators. CCD maintains a social-equity program and best-practices guidance. The Medical Psilocybin Act added an equity fund (about $630,000 appropriated in 2026) to subsidize treatment for patients who cannot afford it.

Expungement: The 2021 legalization law provided for automatic expungement of convictions for cannabis conduct that is now legal, and a 2023 law lets affected people check status and request expedited processing. In practice, automatic expungement has faced implementation delays, so some eligible records have not been cleared promptly. Expungement is limited to cannabis offenses; it does not extend to other controlled-substance convictions.

Market and barriers

Hard numbers (verify against current CCD data before publication): - Excise tax: 13% as of July 2025, rising 1 point per year to 18% by 2030, plus gross receipts tax (about 5% base, varies locally). Medical sales exempt. - License caps: none statewide. Residency requirement: none. Vertical integration: permitted. - Plant limits: Producer Microbusiness capped at 200 mature plants; home grow 6 mature/6 immature per adult, 12 mature per household. - Licensees: roughly 380 licensed cannabis companies reporting activity by May 2025, up from about 78 in April 2022; roughly one-third of companies that once reported sales have since closed amid oversaturation (about 194 exits reported). - Sales: more than $428 million in the first nine months of 2025; cumulative cannabis revenue reportedly approaching $2 billion since launch, with monthly sales around $40 million. - Specific dollar license-fee figures were not captured in the sources reviewed; verify on the CCD site.

Enclosure read

New Mexico is one of the more open adult-use markets in the country: no license caps, no residency rule, low-cost microbusiness tiers, vertical integration permitted, and legal home grow. That design deliberately lowered the fence for small operators, and the result was a flood of small licensees rather than MSO consolidation. The pressure is now coming from two directions. First, market economics: oversaturation and collapsing wholesale prices have already shaken out roughly a third of operators, which consolidates surviving share even without a legal cap, fencing out undercapitalized small businesses by attrition. Second, the hemp side is being fenced hard: the September 2025 NMED emergency rule plus the federal November 12, 2026 hemp redefinition will push intoxicating hemp products either out of the market or into the licensed (and taxed) cannabis channel, favoring established cannabis licensees over independent hemp retailers and DIY home processors. Psychedelic access is fenced by design, restricted to diagnosed patients and licensed clinicians, not open personal use. Net: the legal scaffolding is genuinely open for cannabis, but economic shakeout and the hemp clampdown are tightening real-world access. That balance lands at a moderate enclosure pressure score of 3/5.

What to watch next

  • November 12, 2026: federal hemp redefinition (total-THC standard, 0.4 mg per container cap) takes effect; watch NMED enforcement and any conforming state action.
  • December 2026: targeted launch of the Medical Psilocybin Program; watch Department of Health rule finalization and Advisory Board meetings.
  • December 31, 2027: statutory backstop deadline for the psilocybin program.
  • January 2027: new governor takes office (Lujan Grisham term-limited); 2026 gubernatorial election outcome will shape 2027 drug policy.
  • 2027 regular session: New Mexico holds a longer 60-day session in odd years (convening January 2027), the likely venue for any renewed cannabis workplace-protection, hemp, or expungement-cleanup bills; the 2026 session has already adjourned.
  • 2026 Farm Bill: watch whether Congress modifies the hemp ban before November 12, 2026 (House version so far leaves it intact).

Regulators

  • Cannabis Control Division (CCD), within the Regulation and Licensing Department (RLD): licensing, compliance, enforcement for adult-use and medical cannabis (https://www.rld.nm.gov/cannabis/).
  • New Mexico Environment Department (NMED) and the Environmental Improvement Board: hemp and hemp finished-product manufacturing/retail rules (intoxicating-hemp emergency rule).
  • New Mexico Department of Health (DOH): Medical Cannabis Program patient registry; Medical Psilocybin Program and Advisory Board; Harm Reduction Program (syringe services, naloxone, drug checking) (https://www.nmhealth.org/).
  • New Mexico Taxation and Revenue Department: Cannabis Excise Tax administration (https://www.tax.newmexico.gov/businesses/cannabis-excise-tax/).

Federal exposure (2026)

New Mexico runs a fully legal adult-use market, a tax-exempt medical program, a launching therapeutic psilocybin regime, and strong harm reduction, every one of which now sits in tension with a federal posture that medicalizes and controls rather than legalizes. The relevant federal levers as of mid-2026:

Rescheduling and 280E. Cannabis remains Schedule I by default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; adult-use (recreational) cannabis stays Schedule I. For New Mexico that split matters because the state runs both channels. The state's medical cannabis operators (already excise-exempt and gross-receipts-exempt under state law) gain the federal tax benefit of escaping IRS Section 280E, which bars ordinary business deductions for Schedule I and II traffickers; medical-designated cannabis activity moving to Schedule III ends 280E for that category only. The much larger adult-use side, the bulk of New Mexico's roughly $2 billion in cumulative sales, remains Schedule I and keeps eating the 280E penalty, paying federal tax on gross profit with no deduction for rent, payroll, or marketing. The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027; even if it ultimately moves all cannabis to Schedule III, that does not legalize cannabis, does not authorize interstate commerce, and does not cover state recreational businesses. Practical effect: a tax-relief wedge that favors New Mexico's medical operators and leaves the adult-use majority where it was.

The November 12, 2026 hemp cliff. This is New Mexico's sharpest near-term federal exposure on the supply side. The FY2026 agriculture appropriations law (Section 781, Rep. Andy Harris R-MD) narrowed the federal definition of hemp to a total-THC standard capping finished products at about 0.4 mg total THC per container, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The proposed H.R.7010 delay was not enacted, and the 2026 Farm Bill (H.R.7567) keeps the ban. New Mexico is comparatively well-positioned because the state already moved first: the NMED emergency rule effective September 1, 2025 banned chemically converted and synthetic cannabinoids (delta-8, delta-10, THC-O, HHC). The state rule and the federal redefinition stack to fence the intoxicating-hemp side from both directions. Practical effect: synthetic and high-dose hemp THC products sold outside the licensed cannabis channel lose their legal footing, and the remaining low-dose hemp THC market sold in gas stations and smoke shops is largely recriminalized at the federal level; demand that survives is pushed into the regulated, taxed CCD cannabis system, which structurally advantages licensed cannabis operators over independent hemp retailers.

Banking. SAFER Banking has stalled in Congress, so there is no federal safe-harbor for financial institutions serving cannabis businesses. New Mexico operators, especially the undercapitalized microbusinesses the state encouraged, remain largely cash-reliant or dependent on a thin set of state-chartered credit unions, paying elevated fees and bearing security and audit costs. Schedule III for the medical category does not by itself fix banking access, since the activity is still federally controlled and the SAFER framework is what banks have been waiting on.

Psychedelics. This is the cleanest state-versus-federal collision in the brief. Psilocybin, MDMA, and ibogaine remain Schedule I federally. New Mexico's Medical Psilocybin Act (SB 219, 2025) makes it the third state to authorize therapeutic psilocybin, with a program targeted to launch by December 2026; that launch will put licensed New Mexico providers in possession of and administering a Schedule I substance under state law, creating direct state-federal tension and continued federal criminal exposure no matter how tightly the state program is run. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority review vouchers fast-track FDA review of psychedelic therapies, but there is no FDA approval yet. If and when the FDA approves a psilocybin product, DEA would reschedule that specific approved drug (the same mechanism that just moved FDA-approved cannabis drugs to Schedule III), which would relieve federal exposure for that approved formulation prescribed through normal medical channels; it would not by itself legalize New Mexico's broader supervised-therapy model, its state-licensed administration setting, or any non-approved psilocybin the program uses. Until then the program launches squarely inside federal prohibition.

Harm reduction. New Mexico's harm reduction infrastructure is comparatively strong: a long-standing Harm Reduction Act, statewide syringe services, free-by-mail naloxone, and legal fentanyl and xylazine test strips. That strength is now exposed to a federal funding cut. The SAMHSA guidance dated April 24, 2026 bars federal funds from paying for fentanyl test strips, clean syringes, and sterile water; naloxone remains federally supported. Practical effect: New Mexico can keep distributing test strips and syringes only to the extent it backfills with state dollars or non-federal funding, so the federal lever here is fiscal rather than criminal, and it pressures exactly the drug-checking and syringe-access pieces the state has built out.

The fentanyl backdrop is set: the HALT Fentanyl Act (July 17, 2025) permanently placed fentanyl-related substances in Schedule I, which intersects New Mexico's no-broad-decriminalization stance and its harm reduction model rather than its cannabis market.

Patient access and rights

This section covers what New Mexico law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): New Mexico has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; New Mexico is not among them. The absence is the finding: a New Mexico patient has no enforceable right to use their medicine in a hospital today.

Broader protections: New Mexico protects a qualified patient in five of the six areas, with housing the exception. Employment is protected under the Lynn and Erin Compassionate Use Act, NMSA Section 26-2B-9, which bars an employer from taking adverse action based on a positive test or program enrollment, subject to limited exceptions. A separate provision in the Children's Code, NMSA Section 32A-3A-15, protects custody and the removal of children (subsection (B)), school enrollment (subsection (C)), and provides that for the purposes of medical care, including organ transplants, authorized use is treated as the equivalent of any other prescribed medication (subsection (D)). A review of New Mexico law found no housing protection for a patient as such; that gap is the finding.

Out-of-state patients: New Mexico offers full reciprocity; a qualifying patient from a reciprocal program may purchase directly at a New Mexico dispensary.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and New Mexico has not enacted a Ryan's Law. The broader protections above are a creature of New Mexico law, not federal law.

Sources: New Mexico employment protection, NMSA Section 26-2B-9; custody, school, and transplant protections, NMSA Section 32A-3A-15.

Related reading from Drug Policy Watch: the Federal Drug Policy Brief, the Schedule III rescheduling explainer, and the 50-State Matrix.

Analysis: the enclosure read in depth

New Mexico is one of the most open legal cannabis markets in the country, and the enclosure pressure here is real but comes more from economics and the hemp clampdown than from the licensing rules themselves. The state design points the other way from enclosure: no statewide license caps, no residency requirement, vertical integration permitted, cheap microbusiness and integrated-microbusiness tiers built specifically to let small and disadvantaged operators in, and legal home grow up to 6 mature plants per adult (12 per household). Those are commons-preserving features, deliberate counter-moves against the consolidation seen in capped markets.

Who is fenced out, and who consolidates. The fencing is happening by attrition rather than by statute. Oversaturation and collapsing wholesale prices have already shaken out roughly a third of the operators that once reported sales (about 194 exits against roughly 380 active licensees by May 2025). Open entry flooded the market, prices fell, and undercapitalized small operators, exactly the microbusinesses the equity framework recruited, are the ones closing. Surviving share concentrates in better-capitalized operators even with no legal cap, so the open-door policy produces a delayed, market-driven consolidation. The federal banking gap (stalled SAFER Banking) sharpens this by raising the cost of capital most for the smallest players. On the hemp side the fencing is explicit: the September 2025 NMED rule plus the November 12, 2026 federal redefinition push intoxicating-hemp products out of independent retail and toward the licensed, taxed cannabis channel, fencing out independent hemp shops and DIY processors and handing that residual demand to CCD licensees.

State-plus-federal interaction. The two layers compound. Federally, the medical category gets 280E relief from Schedule III while the adult-use majority stays Schedule I and keeps the tax penalty; this nudges value toward the medical track and toward operators big enough to optimize across both. On hemp, state and federal restrictions stack in the same direction. The psychedelics interaction is the starkest: New Mexico is standing up a state-licensed psilocybin therapy program inside ongoing federal Schedule I prohibition, and even a future FDA approval would relieve only the specific approved drug, not the state's broader supervised-access model, so the state is absorbing federal legal risk on behalf of patients and licensed providers. Harm reduction shows a fiscal version of the same squeeze: strong state programs now partly defunded by the April 2026 SAMHSA bar on federal money for test strips and syringes.

Where the commons counter-moves are. New Mexico retains genuine de-enclosure valves: legal home grow keeps a non-market path to cannabis that no consolidation can fully close; the microbusiness and integrated-microbusiness tiers and the social-equity discounts keep the legal on-ramp cheap; and the psilocybin equity fund (about $630,000 appropriated in 2026) is an explicit attempt to keep therapeutic access from becoming a luxury good. These are why the score is not higher.

What to watch. Whether the post-shakeout market restabilizes with a durable small-operator tier or keeps consolidating; NMED enforcement intensity after November 12, 2026; whether the state backfills harm reduction supplies cut by SAMHSA; whether the psilocybin program launches on its December 2026 target and how it manages federal exposure; and the January 2027 gubernatorial transition plus the longer 2027 60-day session, the likely venue for any cleanup or tightening.

Why 3 out of 5. The licensing architecture is among the least enclosed in the country, and home grow plus cheap microbusiness tiers are live commons counter-moves, which pulls the score down. But economic shakeout is consolidating real-world share, the hemp side is being fenced hard from both state and federal directions, banking access remains gated by stalled federal reform, and psychedelic and broader-substance access are fenced by design and by federal prohibition. The open scaffolding and the tightening real-world access roughly offset, landing at a moderate 3 out of 5.

Active legislation (2026)

The 2026 regular session was a short 30-day budget session that has already adjourned (roughly mid-February 2026), so there is no active in-session cannabis/psychedelic/hemp legislation as of June 2026. The table below logs significant recent and 2026-session items. Bill numbers, sponsors, and outcomes flagged "unconfirmed" should be verified before publication. This list is not exhaustive; use the live trackers linked below for the long tail.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

  • HB 52 (recent) Harm Reduction Act amendment; expand drug-checking supplies (Reported passed; session/enactment unconfirmed)
Bill Title/Topic Chamber Status Sponsor(s)
SB 219 (2025) Medical Psilocybin Act Senate (origin) Signed into law April 2025; rulemaking underway, launch targeted Dec 2026 Unconfirmed primary sponsor(s) (verify)
HB 346 (2026) Hemp finished-products definitions; ban semi-synthetic/synthetic cannabinoids; hemp retailer regulation House Considered in 2026 session; final status unconfirmed Unconfirmed (verify)
HB 294 (2026) Cannabis child-safety packaging (black-and-white, ban youth-appealing designs) House Reported as not passed in 2026 session Unconfirmed (verify)
HB 230 (2025) Medical cannabis workplace protections; limit random testing of patients House Passed House March 12, 2025; final enactment unconfirmed Rep. Reena Szczepanski; Rep. Elizabeth Thomson
SB 269 (2025) Companion medical-cannabis workplace protections Senate 2025 session; final status unconfirmed Sen. Linda Lopez
HB 52 (recent) Harm Reduction Act amendment; expand drug-checking supplies House Reported passed; session/enactment unconfirmed Unconfirmed (verify)

Live trackers: LegiScan New Mexico (https://legiscan.com/NM); New Mexico Legislature (https://www.nmlegis.gov); Marijuana Moment (https://www.marijuanamoment.net); ACLU-NM 2026 session (https://www.aclu-nm.org/2026-leg-session/).

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →

Sources